epilepsyにおける突然の予期せぬ死の危険因子:ケース・コントロール研究
L Nilsson1, B Y Farahmand, P G Persson
1Department of Neurological Rehabilitation, Stora Sköndal Hospital, Sweden. lena.weine@swipnet.se
Lancet (London, England)
|March 27, 1999
まとめ
予期せぬ突然死 (SUDEP) のリスクは,発作の頻度やポリセラピーにより増加します. 早期発症と抗薬の頻度の変化もリスク要因です. 発作制御を改善することで,SUDEPを減らすことができます.
科学分野:
- 神経学 神経学とは
- エピレプシの研究研究
- 公衆衛生は公衆衛生である.
背景:
- 急性予期せぬ死 (SUDEP) は,一般人よりも患者でより頻繁に発生する重大な懸念事項です.
- SUDEPに関連する臨床的変数を特定することは,リスクの階層化と予防に不可欠です.
研究 の 目的:
- 臨床的変数と突然の予期せぬ死 (SUDEP) の関連性を調査する.
- エピレプシー患者におけるSUDEPの特定の危険因子を特定する.
主な方法:
- ストックホルム (1980年−1989年) の15~70歳のエピレプシー患者のコホートを用いて,ネストされた症例対照研究が行われました.
- 症例は,エピレプシーで死亡し,SUDEPの基準を満たした個体であり,年齢と性別を合わせた3人の生きたエピレプシー患者のコントロールが1例当たりでした.
- 臨床データを収集し評価するために,医療記録と解剖結果を分析した.
主要な成果:
- 発作頻度が高い (例えば,年間50発以上) により,SUDEPのリスクが著しく増加した (RR 10.16).
- 3つ以上の抗薬 (AED) の併用は,単独療法と比較して,SUDEPのリスク (RR 9.89) を大幅に増加させた.
- 早期発症のエピレプシー (RR 7.72) とAEDの投与量の頻繁な変更 (RR 6.08) が主要なリスク因子として特定されました.
結論:
- 突然の予期せぬ死 (SUDEP) は,発作に関連しており,生命の初期に確立された潜在的な予期せぬ要因があるようです.
- SUDEPのリスク関連における性差は観察され,女性における用量変化との関連はより強く示された.
- 発作制御を改善し,ポリセラピーを避けることは,SUDEPのリスクを軽減するための推奨戦略です.
関連する概念動画
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Drug Toxicity: Risk factors
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
Confounding in Epidemiological Studies
Confounding in statistical epidemiology represents a pivotal challenge, referring to the distortion in the perceived relationship between an exposure and an outcome due to the presence of a third variable, known as a confounder. This variable is associated with both the exposure and the outcome but is not a direct link in their causal chain. Its presence can lead to erroneous interpretations of the exposure's effect, either exaggerating or underestimating the true association. This phenomenon...
Bias in Epidemiological Studies
Biases can arise at various stages of research, from study design and data collection to analysis and interpretation. Recognizing and addressing these biases is essential to ensure the validity and reliability of epidemiological findings.Broadly speaking, biases in epidemiology fall into three main categories: selection bias, information bias, and confounding. A more detailed description of possible biases is:
Coronary Artery Disease III: Clinical Manifestations
Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
Hazard Ratio
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial evaluating a...
For example, in a clinical trial evaluating a...

